Update on Secondary Stroke Prevention with Antithrombotic Drugs


Editors
J.L. Mas, Paris
P.J. Koudstaal, Rotterdam

7 figures and 15 tables, 1997
KAKGER
Supported by an Educational Grant from Sanofi Winthrop

KAHGER

S. Karger
Medical and Scientific Publishers Basel * Freiburg * Paris ■ London New York • New Delhi • Bangkok Singapore ■ Tokyo • Sydney
Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Contents Vol. 7, Suppl. 6, 1997

Cerebrovascular Diseases

1  Introduction
Mas, JX. (Paris); Soudstaal, PJ. (Rotterdam)

2  Platelet Function and Pharmacology of Antiplatelet Drugs
Nurden, A.T.; Guyonnet Duperat, V.; Nurden, P. (Pessac)

10  Aspirin with and without Dipyridamole
Dyken, M.L. (Indianapolis, Ind.)

17  Ticlopidine and Clopidogrel in Secondary Stroke Prevention
Bousser, M.G. (Paris); Roberts, R.S.; Gent, M. (Hamilton, Ont.)

24  Oral Anticoagulants for Secondary Prevention of Stroke
Hart, R.G. (San Antonio, Tex.)

30  Secondary Stroke Prevention with Antithrombotic Drugs: What to Do Next?
van GijnK; Algra, A. (Utrecht)